Literature DB >> 25966900

Cognitive impairment is not a predictor of failure to adhere to anticoagulation of stroke patients with atrial fibrillation.

Solveig Horstmann1, Timolaos Rizos, Michaela Saribas, Evdokia Efthymiou, Geraldine Rauch, Roland Veltkamp.   

Abstract

BACKGROUND: Oral anticoagulation (OAC) with vitamin K antagonists (VKA) or direct oral anticoagulants (DOAC) is an effective strategy that is used for stroke prevention in patients with atrial fibrillation (AF). However, OAC is underused particularly in elderly patients, who are often physically disabled or cognitively impaired. We aimed at evaluating the effect of cognitive status and disability on OAC adherence 1 year after stroke or TIA.
METHODS: In this prospective, single-center, observational study patients with ischemic stroke or TIA were consecutively included between 3/2011 and 9/2012. The detailed medical history, basic demographic variables, cardiovascular risk factors, stroke severity according to the National Institutes of Health Stroke Scale (NIHSS), medication including OAC were all recorded. Cognitive performance was measured using the Montreal Cognitive Assessment (MoCA) score at baseline. The functional status was assessed by recording activities and instrumental activities of daily living, respectively (ADL, IADL). After 12 months, patients had a follow-up visit to reassess the cognitive and functional status (MoCA, ADL and IADL) and to document the current use of OAC.
RESULTS: In total, 12 months after the ischemic stroke or TIA AF had been diagnosed in 160/586 (27.3%). Of these, 151 patients (94.4%) were treated with OAC. OAC was performed using VKA in 79/151 (52.3%) and DOACs in 72/151 (47.7%). Cognitive impairment at 12 months follow-up was not associated with the absence of OAC treatment. However, regression analysis revealed that patients with AF with physical (ADL) and functional disability (IADL) were less likely to be treated with OAC (p = 0.08 and p = 0.04, respectively) 12 months after a stroke. None of these two factors, however, was independently associated with nonadherence to OAC 12 months after stroke. Although cognitive performance was similar in patients receiving VKA and direct anticoagulants (DOAC), adherence to VKA tended to be lower (82.6 vs. 94.6%, p = 0.12).
CONCLUSIONS: In stroke and TIA patients with AF, the multifactorial medical and functional constellation rather than cognitive impairment specifically can be an obstacle for long-term OAC.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25966900     DOI: 10.1159/000381728

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  8 in total

1.  Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach.

Authors:  Carmen Suárez Fernández; Suárez Fernández; Francesc Formiga; Miguel Camafort; María Cepeda Rodrigo; Jose Cepeda Rodrigo; Jesús Díez-Manglano; Antonio Pose Reino; Pose Reino; Gregorio Tiberio; Jose María Mostaza
Journal:  BMC Cardiovasc Disord       Date:  2015-11-04       Impact factor: 2.298

2.  The influence of frailty syndrome on medication adherence among elderly patients with hypertension.

Authors:  Beata Jankowska-Polańska; Krzysztof Dudek; Anna Szymanska-Chabowska; Izabella Uchmanowicz
Journal:  Clin Interv Aging       Date:  2016-12-07       Impact factor: 4.458

3.  Cognitive function and adherence to anticoagulation treatment in patients with atrial fibrillation.

Authors:  Beata Jankowska-Polańska; Lomper Katarzyna; Alberska Lidia; Jaroch Joanna; Krzysztof Dudek; Uchmanowicz Izabella
Journal:  J Geriatr Cardiol       Date:  2016-07       Impact factor: 3.327

4.  Clinical characteristics and type of antithrombotic treatment in a Spanish cohort of elderly patients with atrial fibrillation according to dependency, frailty and cognitive impairment.

Authors:  Jose María Mostaza; Manuel Jesús Romero Jiménez; Fernando José Ruiz Laiglesia; José Antonio Díaz Peromingo; Manuel Beltrán Robles; Ernesto Guevara Sierra; Ana Santander Bilbao; Carmen Suárez
Journal:  J Geriatr Cardiol       Date:  2018-04       Impact factor: 3.327

5.  Clinical presentation, diagnostic findings and management of cerebral ischemic events in patients on treatment with non-vitamin K antagonist oral anticoagulants - A systematic review.

Authors:  Thomas Raphael Meinel; Sebastién Frey; Marcel Arnold; Sarah Kendroud; Urs Fischer; Johannes Kaesmacher; Mirjam Rachel Heldner; Simon Jung
Journal:  PLoS One       Date:  2019-03-29       Impact factor: 3.240

6.  Cognitive Impairment Is Independently Associated with Non-Adherence to Antithrombotic Therapy in Older Patients with Atrial Fibrillation.

Authors:  Hyun-Joo Seong; Kyounghoon Lee; Bo-Hwan Kim; Youn-Jung Son
Journal:  Int J Environ Res Public Health       Date:  2019-07-29       Impact factor: 3.390

7.  Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation.

Authors:  Michaël Benzimra; Béatrix Bonnamour; Martin Duracinsky; Christophe Lalanne; Jean-Pierre Aubert; Olivier Chassany; Isabelle Aubin-Auger; Isabelle Mahé
Journal:  Patient Prefer Adherence       Date:  2018-01-04       Impact factor: 2.711

8.  Prophylactic anticoagulation in patients with glioblastoma or brain metastases and atrial fibrillation: an increased risk for intracranial hemorrhage?

Authors:  Sina Burth; Mona Ohmann; Dorothea Kronsteiner; Meinhard Kieser; Sarah Löw; Lars Riedemann; Mona Laible; Anne Berberich; Katharina Drüschler; Timolaos Rizos; Antje Wick; Frank Winkler; Wolfgang Wick; Simon Nagel
Journal:  J Neurooncol       Date:  2021-03-05       Impact factor: 4.130

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.